WO2009056076A1 - Variantes ingenierizadas de pertactina para uso vacunal - Google Patents
Variantes ingenierizadas de pertactina para uso vacunal Download PDFInfo
- Publication number
- WO2009056076A1 WO2009056076A1 PCT/CU2008/000009 CU2008000009W WO2009056076A1 WO 2009056076 A1 WO2009056076 A1 WO 2009056076A1 CU 2008000009 W CU2008000009 W CU 2008000009W WO 2009056076 A1 WO2009056076 A1 WO 2009056076A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequences
- pertactins
- polynucleotide sequence
- sequence according
- pertactin
- Prior art date
Links
- 108010021711 pertactin Proteins 0.000 title claims abstract description 31
- 229960005486 vaccine Drugs 0.000 title abstract description 38
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 33
- 239000002157 polynucleotide Substances 0.000 claims description 33
- 201000005702 Pertussis Diseases 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 241000588807 Bordetella Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 8
- 238000002649 immunization Methods 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000588780 Bordetella parapertussis Species 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000028996 humoral immune response Effects 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940031567 attenuated vaccine Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 210000003578 bacterial chromosome Anatomy 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000018150 Bordetella infection Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 230000000625 opsonophagocytic effect Effects 0.000 abstract description 10
- 230000005875 antibody response Effects 0.000 abstract description 7
- 230000001681 protective effect Effects 0.000 abstract description 4
- 229960001212 bacterial vaccine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 16
- 101150006855 PRN gene Proteins 0.000 description 12
- 101100137577 Rattus norvegicus Prnp gene Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000004224 protection Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108010081690 Pertussis Toxin Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241001076388 Fimbria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 239000001987 Bordet-Gengou agar Substances 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ALDXNLXJHWOGNT-UHFFFAOYSA-N 1h-imidazole;zinc Chemical compound [Zn].C1=CNC=N1 ALDXNLXJHWOGNT-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101710118506 69 kDa protein Proteins 0.000 description 1
- 101710191936 70 kDa protein Proteins 0.000 description 1
- 241001495147 Bordetella holmesii Species 0.000 description 1
- 241001406043 Bordetella pertussis Tohama I Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101100048413 Escherichia coli (strain K12) ulaC gene Proteins 0.000 description 1
- 101000935612 Gloydius halys Bradykinin-potentiating peptide 1 Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010073429 Type V Secretion Systems Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 101150112048 apxIIIA gene Proteins 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 101150077469 prnA gene Proteins 0.000 description 1
- 101150103042 ptxA gene Proteins 0.000 description 1
- 101150098102 ptxC gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is framed in the field of biomedicine, specifically in the engineering of the pertactin protein (Pm) for use in acellular vaccines against Bordetella pertussis.
- the engineered pertactins encompass in their structure the polymorphism of different strains and when tested as vaccines they induce an antibody response of greater protective capacity and greater opsonophagocytic activity.
- Pertussis, Coqueluche or Pertussis is an acute, highly infectious respiratory disease caused by the Bordetella pertussis bacteria, a microorganism first isolated in 1906 by Bordet and Gengou [Bordet, J. and O. Gengou. Ann Inst Pasteur (Paris), 1906. 20: p. 731-41]. Recently it was estimated that the annual morbidity of infected people in the world is 48.5 million. In children under 6 months, the disease is particularly severe, with 90% of the total number of deaths associated with this population subgroup (300-400 thousand) [Crowcroft, N. S., et al. Lancet Infect Dis, 2003. 3 (7): p. 413-8]. There are several types of vaccines against B.
- pertussis comprised in two large groups: cell vaccines and the most recent, of the acellular type. Due to the effect of vaccination there has been a dramatic decrease in the incidence of disease, and there has also been a shift in the incidence of cases, moving from children to adolescents and adults. Numerous studies show that adolescents are the fundamental reservoir of B. pertussis, and that these constitute the fundamental source of contagion for partially protected children. Therefore, whooping cough is still an unsolved problem, so it is necessary to develop new vaccines for better control of the epidemic, reemerging outbreaks and possible eradication of this disease in the regions of endemism [Cherry, JD Pediatrics, 2005. 115 (5): p. 1422-7; Singh, M. and K. Lingappan, Chest, 2006. 130 (5): p. 1547-53].
- the Bordetella genus comprises nine species, of which four have been associated with infections in mammals, namely B. holmesii, B. bronchiseptica, B. parapertussis and B. pertussis, the last two being the fundamental actors of human infections [Mattoo, S., et al. Front Biosci, 2001. 6: p. E168-86]. Most virulence factors are regulated at the transcriptional level by a two-component system called BvgA / S (Bordetella virulence Activator / Sensor genes) [Stibitz, S., et al. Nature, 1989. 338 (6212): p. 266-9].
- Pm Pertussis toxins (from the English pertussis toxin, abbreviated PT), Trachea Colonization Factor, Adenylate Cyclase; and the adhesives Phytohemagglutinin filamentous (FHA), Fimbria (Fim) and pertactin (Pm), a protein on which the present invention focuses.
- Pm is an outer membrane protein, which belongs to the family of type V autotransporters. It is characterized by catalyzing its own transport through the outer membrane. [Henderson, IRTrends Microbiol, 2000. 8 (12): p. 534-5].
- Mature Pm is a 68-kDa, 69-kDa and 70-kDa protein in B.
- bronchiseptica Henderson, IR Infec ⁇ Immun, 2001. 69 (3): p. 1231-43.
- B. pertussis [Char ⁇ es, LG. , et al. Proc Nati Acad Sci USA, 1989. 86 (10): p. 3554-8.]
- B. parapertussis [Li, LJ. , et al. Mol Microbiol, 1991. 5 (2): p. 409-17], respectively.
- the structure consists of 16 parallel strands in ⁇ -helix and a V-shaped cross section [Emsley, P., et al. Nature, 1996. 381 (6577): p. 90-2.]. From this helical core numerous loops are projected.
- Acellular vaccines may consist of: 1) a component of Pertussis Toxin (PT), 2) two components: PT and Phytohemagglutinin filamentous (FHA), 3) three components: PT, FHA and Prn, and 4) five components, which includes the three previous components and Fimbria 2 (FIM2) and Fimbria 3 (FIM3).
- PT Pertussis Toxin
- FHA Phytohemagglutinin filamentous
- FHA Phytohemagglutinin filamentous
- Prn is one of the proteins with the highest polymorphism in B. pertussis.
- region 1 region 1
- region 2 region 2
- PQP Pro-GIn-Pro
- the R1 region is located in a protuberant loop near the amino terminal (N-term) end and adjacent to the RGD motif
- the R2 region is located towards the carboxyl terminal (C-term) end [Hijnen, M., et al. Infect Immun, 2004. 72 (7): p. 3716-23.].
- a total of 12 variants of Prn (Prn1, Prn2, Prn3 ... Pm12) have been identified, for B.
- the present invention has as main objective to contribute to the development of more effective acellular vaccines against pertussis.
- the main works that precede the present invention, with a view to finding more effective vaccines, are based on obtaining immunogenic preparations by applying mixtures of Pm (Nicole Guiso et al., WO 01/90143 A2 and US 2006/0008474 A1) or synthetic peptides from the R1 region of Prn (Frederik Mooi et al., WO 02/00695 A2). Therefore, an important problem of the prevention of pertussis is to achieve the development of more effective acellular vaccines.
- This invention contributes to solving the aforementioned problem, and is part of the engineering of the prnA gene, coding for the ⁇ outer membrane protein.
- pertussis called Pertactin (Pm).
- the invention covers the needs evidenced in the state of the art, making it possible to obtain different variants of engineering pertactins, so that in a single molecule two different polymorphic domains of the R1 region of Pm are understood.
- the versatility of the invention provides for the engineering of new Pm, additionally comprising three or more different polymorphic domains of the R1 region.
- the object of the present invention is a polynucleotide sequence encoding an engineered pertactin protein, comprising up to the first 300 amino acids near the N-terminal end of a given type of pertactin natura! mature (PmX300) and an amino acid sequence comprising up to the last 620 amino acids near the C-terminal end of a given type of mature natural pertactin (PmY620), which results in a PrnX300- PrnY620 engineered pertactin.
- engineing pertactin refers to a protein that results from coupling, adjacent or not, a fragment comprising up to the first 300 amino acids near the N-terminal end of a mature natural pertactin molecule to another fragment containing up to the last 620 amino acids near the C-terminal end of a mature natural pertactin molecule.
- the new variants of engineering pertactins are obtained by molecular mutagenesis, by adjacently coupling sequences comprising up to 300 amino acids near the N-terminal end of a given type of mature natural pertactin, to sequences comprising up to the last 620 amino acids near end C -terminal of a given type of mature natural pertactin.
- the new immunized Pm comprises sequences of different types of Pm in a single molecule, without affecting the protective immune response.
- different engineering variants of Pm encoded by the nucleic acid sequences identified as SEQ ID No 1- SEQ ID No 6 are obtained.
- the fragment of the first 300 amino acids near the N-terminal end of a given type of mature natural pertactin correspond to pertactins of the genus Bordetella.
- this fragment corresponds to pertactins of B. pertussis or B. parapertussis, preferably to the variants Pm1, Pm2 and Prn3 of B. pertussis.
- the last 620 amino acids near the C-terminal end of a given type of pertactin natura! mature correspond to pertactins of the genus Bordetella.
- the PmY620 fragment corresponds to pertactins of f ⁇ . pertussis and S. parapertussis, preferably to the Prn1, Pm2 and Prn3 variants of ⁇ . pertussis
- the polynucleotide sequence of the present invention encodes a polypeptide chain comprising any possible combination of given types of pertactins in the PrnX300-PrnY62Q format.
- the amino acid sequences PrnX300 and PrnY620 are coupled adjacently, or by the use of the sequences IDNATWVMTDN or IDNATWVMTDNIDNATWVMTDN.
- the PrnX300 and PmY620 amino acid sequences can be devoid of repeated sequences, preferably the GGXXP and PQP sequences of the R1 and R2 regions.
- Region 1 which comprises the repeated sequences GGXXP is weakly recognized by human and rabbit sera, indicating that it is not an immunodominant region [Hijnen, M., FR Mooi, et al. (2004). Infect Immun 72 (7): 3716-23].
- GGXXP deletions do not significantly affect the structural properties, since Prn mutated in region 1 are recognized by conformational monoclonal antibodies (AcM) generated against natural pertactins, and not by sequential anti-GGXXP mAbs. Additionally, it has been observed that certain mutations in regions 1 can increase the binding capacity of certain conformational mAbs. Finally, there is evidence indicating that region 1 (GGXXP) and region 2 (PQP) form a unique epitope [Hijnen, M., R. de Voer, et al. (2007). Vaccine 25 (31): 5902-14].
- the object of the present invention is also a polynucleotide sequence that codes for an engineered pertactin, where the amino acid sequences PmX300 and PmY620 comprise peptides that function as helper T epitopes, preferably Diphtheria, Tetanus, HBV, Poliovirus, Vaccina, HIV and Influenza epitopes. It is known by people versed in this field of The technique that the insertion of this type of epitopes leads to an increase in the immune response generated by the molecules that possess them.
- the object of the present invention are also polynucleotide sequences according to claim 1, wherein the polynucleotide sequence is optimized in its use of codons, for its expression in bacteria, yeasts, insect or mammalian cells.
- the present invention includes the generation of engineering pertactins that contemplate in a single molecule different polymorphic regions from different species of the genus Bordetella.
- the engineering pertactin object of the present invention was not only capable of generating an effective response against different strains of B. pertussis, which express Prn1 and Prn2, but also induced a more effective antibody response with respect to natural proteins, evidenced in the respiratory challenge model and in the opsonophagocytosis trial.
- the response induced by the engineering pertactin was, in addition, superior to that of an equimolar mixture composed of Pm 1 and Prn2 (Pm1 + Prn2).
- Vaccine compositions based on mixtures of different pertactins of one species or of different species, although they cover polymorphism, lead to technological difficulties associated with production processes, such as an increase in the concentration of pollutants and inconsistency in batch production. , among others. This is an aspect of vital importance for the development of combined vaccines, where multiple antigens of different characteristics are involved, which can compromise the systemic immunogenicity of the formulation.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more engineering pertactins, encoded by the polynucleotide sequences of claims 1 to 13, which in sufficient quantities generate a humoral immune response and Cellular effective against species of the genus Bordetella, by an immunization procedure in mammals, preferably in humans.
- the pharmaceutical composition comprises one or more engineering pertactins generates an effective humoral and cellular immune response against B. pertussis.
- the object of the present invention is also a live or attenuated vaccine comprising one or more engineering pertactins, encoded by the polynucleotide sequences of claims 1 to 13, wherein the engineering pertactin is preferably expressed in the outer membrane.
- the polynucleotide sequences of claims 1 to 13 may be comprised in a plasmid vector or in the bacterial chromosome.
- the polynucleotide sequences of claims 1 to 13, which code for degenerate pertactins are comprised in a mammalian expression vector.
- Said expression vector which contains the polynucleotide sequences of claims 1 to 13, is the basis of a nucleic acid vaccine, also object of the present invention.
- the polypeptide sequences encoded by the polynucleotide sequences of claims 1 to 13 can be used in a method for the detection of infection by Bordetella.
- the object of this invention is also a diagnostic kit for the detection of the presence or absence of antibodies against Bordetella, comprising polypeptide sequences encoded by the polynucleotide sequences of claims 1 to 13.
- FIG. 1 Protection experiment in vaccinated Balb / c mice with different variants of recombinant and engineered pertactins. Strains of B. pertussis Tohama I (Pm1) and clinical isolation CH53 (Pm2) were used for the challenge. The bars represent the average logarithm of reduction of viable cells in the lung, relative to the control group immunized with PBS.
- FIG. 1 Opsonophagocytosis mediated by sera from Balb / c mice vaccinated with the different variants of recombinant and engineered pertactins.
- the graph shows the difference in fluorescence (Phycoerythrin, from English phycoerithrin, abbreviated PE) in arbitrary units (UA) of cells marked with fluorescein isothiocyanate (from English fluorescein isothiocyanate, abbreviated FITC), of two incubation conditions (PE4 ° C - PE37 ° C).
- the prnA1 and prnA2 genes of the ⁇ strains were amplified by Polymerase Chain Reaction (PCR) from genomic DNA using oligonucleotides 1 and 2, previously reported [Hijnen, M., P. G. van Gageldonk, et al. (2005). Protein Expr Purif 41 (1): 106-12].
- the fragments obtained were cloned into the vector pET-28 a (Novagen) using the Nde I and BamH I sites.
- the reverse CPR method previously described by Imai et al. In 1991 [Imai, Y., et al. Nucleic Acids Res, 1991. 19 (10): p. 2785].
- Table 1 shows the oligonucleotides used for the amplification of the different sequences.
- the pair of oligonucleotides 1, 2 was used to linearize the vectors pET28apm1 and pET28aprn2, corresponding to pertactins 1 and 2, respectively.
- DomR1 fragments were obtained by amplifying with oligonucleotides 3 and 4.
- this region was amplified using oligonucleotide sets 3.5 and 3.6, to add sequences encoding the short and long connectors, respectively.
- Table 2 summarizes the conditions used in the PCR amplification of the different fragments used in the invention.
- the bacterial cream corresponding to each variant was resuspended in rupture buffer (at a concentration of 100 mg / ml cells) and the cells were broken by ultrasound.
- the cell precipitate was solubilized in 8M urea and fractionated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (Sodium Dodecyl Sulphate Polyacrylamid ⁇ GeI Electrophoresis, abbreviated SDS-PAGE) (12.5%).
- the gel was stained by Imidazol-Zinc reverse staining, and the band corresponding to the protein of interest was passed through a 100 ⁇ M steel membrane, in the presence of extraction buffer.
- the extracted protein was renatured and concentrated by Ultrafiltration, using an Amicon concentration cell, with a 50 kDa membrane, and the concentration was determined by the bicinconinic acid method. No contaminants were detected, by testing 15 ⁇ g of the purified proteins in analytical gels of SDS-PAGE stained with Coomassie blue, evidencing that the preparations contained a purity greater than 95% or more.
- Table 3 The characteristics of the different constructions and engineering Pm obtained are summarized in Table 3.
- DC Short Connector
- CL Connect Long
- mice were immunized with 0.2 ⁇ g, 0.02 ⁇ g, or in the absence (PBS), of the recombinant proteins Prn1, Pm2, an equimolar mixture of Prn1 and Pm2 (Prn1 + Pm2), and of the 6 variants of the engineered Pm (shown in Table 3) formulated in aluminum hydroxide.
- the doses correspond to 1/40 and 1/400 of the dose used in humans (Infanrix®, 8 ⁇ g).
- the immunization route used was subcutaneous, using a volume of 100 ⁇ l.
- Sera from immunized mice were evaluated by an ELISA immunoenzymatic assay.
- Antibody titers reached mean values between 1.2x10 3 and 4.6x10 4 .
- the means of the titers corresponding to the higher dose differed significantly from the titers achieved with the lowest dose used (p ⁇ 0.05, Kruskal Wallis-Dunns). No differences were observed for the antibody response generated with pertactins 1 and 2, and the equimolar mixture Pm1 + Prn2. Similarly, no differences were observed between the average of the titles for the different engineering variants. Surprisingly, the titles of the engineered variants were significantly higher than the non-engineered recombinant pertactins (p ⁇ 0.01, Kruskal Wallis-Dunns). For the intranasal challenge, the Tohama I strain (Pm1) and the clinical isolation CH53 (Pm2) were used.
- the bacteria were grown in Bordet-Gengou Agar (Sigma) medium plates supplemented with 1% glycerol and 14% defibrinated sheep blood. The plates were incubated for 24h (at 37 ° C) and the colonies were resuspended in Stainer-Shoulte medium at a density of 10 8 cells / ml. This suspension was used for the intranasal challenge.
- the immunized mice were challenged 15 days after the last immunization, by instilling 50 ⁇ l (5 x 10 6 cells) of the bacterial suspension. Five days after the challenge, the mice were sacrificed and the lungs removed aseptically, and homogenized to measure the bacterial load [Denoel, P., et al.
- Opsonophagocytic activity mediated by anti-Prn antibodies has been shown to be a crucial parameter in the response of vaccinated with acellular vaccines [Hellwig, SM, et al. J Infected Dis, 2003. 188 (5): p. 738-42].
- Opsonophagocytic activity was studied by means of the aforementioned procedure adapted to the mouse model.
- the Tohama I and CH53 strains of B. pertussis were grown in Bordet-Gengou-Agar medium and labeled (2 x 10 6 colony forming units) with FITC.
- the labeled bacteria were opzoned with sera from mice immunized with the recombinant proteins Prn1, Prn2, Prn1 + Pm2 and with two variants of the engineering Prn (Prn2-CC-Prn1 and Pm2-CL-Pm1, for 30 min at 37 0 C, on plate shaker
- the opsonized bacteria and the non-opsonized control were incubated with the polymorphonuclear cells (PMN)
- the samples were divided and incubated for another 45 min, at 4 0 C or 37 0 C.
- the samples were incubated another 30 min at 4 0 C. with the goat anti-mouse-PE conjugate.
- the prnA1, prnA2 and Prn2CCPrn1 and Prn2CLPrn1 gene variants were amplified by PCR from their respective expression vectors (See Table 3), and using oligonucleotides 1 and 2, previously reported [Hijnen, M., PG van Gageldonk , et al. (2005). Protein Expr Purif 41 (1): 106-12], with a modification in oligonucleotide 1, where the Nde I site of oligonucleotide 1 is replaced by the BamH I site.
- the fragments obtained were cloned into the pAEC-SPE3 vector using the BamH I site [Herrera AM, Rodr ⁇ guez EG, et al.
- This vector is designed for extracellular expression of antigens in mammalian cells.
- the vectors were purified using the commercial case (Qiagen®) for plasmid purification.
- Groups of female Balb / c mice (6-7 weeks) were immunized three times with 100 ⁇ g of DNA, intramuscularly, at a concentration of 1 ⁇ g / ⁇ L, in PBS, at three-week intervals.
- the control group was immunized in the same way, using plasmid without insert (pAEC-SPE3). Fifteen days after the last inoculation the mice were sacrificed, and the blood was collected for the evaluation of the sera.
- the specific IgG present in the sera was evaluated, by means of the ELISA technique, using a 1/1000 dilution and coating with equimolar amounts of the Pm1 (2 ⁇ g / mL) and Prn2CCPrn1 (2.4 ⁇ g / mL) proteins.
- animals immunized with the different plasmids expressing Pm1, Pm2, Pm2CCPm1 and Prn2CLPm1 generated a specific immune response (IgG), and significantly higher (p ⁇ 0.001), compared to animals immunized with pAEC-SPE3 (vector without insert).
- the sera generated in the immunized mice recognized to a greater extent (p ⁇ 0.05) the engineering variant Pm2CCPm1 than the natural protein Pm1, which could due to a better exposure of the epitopes shared in Prn2CCPm1 with respect to Pm1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/739,658 US8569470B2 (en) | 2007-10-30 | 2008-10-17 | Engineered pertactin variants for vaccine use |
CA2702697A CA2702697A1 (en) | 2007-10-30 | 2008-10-17 | Engineered pertactin variants for vaccine use |
MX2010004706A MX2010004706A (es) | 2007-10-30 | 2008-10-17 | Variantes ingenierizadas de pertactina para uso vacunal. |
EP08845509A EP2216045A1 (en) | 2007-10-30 | 2008-10-17 | Engineered pertactin variants for vaccine use |
BRPI0817898 BRPI0817898A2 (pt) | 2007-10-30 | 2008-10-17 | Sequência polinucleotídica, composição farmacêutica, vacina, vetor de expressão em mamíferos, vacina, método para a deteccção de infecção por bordetella, e, kit diagnóstico para a detecção de presença ou ausência de anticorpos contra bordetella |
RU2010121646/10A RU2499046C2 (ru) | 2007-10-30 | 2008-10-17 | Полинуклеотидная последовательность, кодирующая сконструированный белок пертактин, вектор, включающий такую последовательность, и вакцинные композиции, содержащие белок пертактина или вектор |
CN2008801141194A CN101878038B (zh) | 2007-10-30 | 2008-10-17 | 用于疫苗用途的经改造的百日咳杆菌粘附素变体 |
US13/966,948 US20140011216A1 (en) | 2007-10-30 | 2013-08-14 | Engineered pertactin variants for vaccine use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2007-0240 | 2007-10-30 | ||
CU20070240A CU23679A1 (es) | 2007-10-30 | 2007-10-30 | Variantes de pertactinas para uso vacunal |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/966,948 Division US20140011216A1 (en) | 2007-10-30 | 2013-08-14 | Engineered pertactin variants for vaccine use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009056076A1 true WO2009056076A1 (es) | 2009-05-07 |
Family
ID=40473455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2008/000009 WO2009056076A1 (es) | 2007-10-30 | 2008-10-17 | Variantes ingenierizadas de pertactina para uso vacunal |
Country Status (11)
Country | Link |
---|---|
US (2) | US8569470B2 (es) |
EP (1) | EP2216045A1 (es) |
KR (1) | KR20100093548A (es) |
CN (1) | CN101878038B (es) |
AR (1) | AR069086A1 (es) |
BR (1) | BRPI0817898A2 (es) |
CA (1) | CA2702697A1 (es) |
CU (1) | CU23679A1 (es) |
MX (1) | MX2010004706A (es) |
RU (1) | RU2499046C2 (es) |
WO (1) | WO2009056076A1 (es) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090143A2 (en) | 2000-05-25 | 2001-11-29 | Institut Pasteur | Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions |
WO2002000695A2 (en) | 2000-06-30 | 2002-01-03 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2539715C (en) * | 2003-10-02 | 2015-02-24 | Glaxosmithkline Biologicals S.A. | Pertussis antigens and use thereof in vaccination |
UA40596U (ru) * | 2006-05-16 | 2009-04-27 | Институт Проблем Безопасности Атомных Электростанций Национальной Академии Наук Украины | Энергоблок атомной электростанции |
-
2007
- 2007-10-30 CU CU20070240A patent/CU23679A1/es not_active IP Right Cessation
-
2008
- 2008-10-17 CN CN2008801141194A patent/CN101878038B/zh not_active Expired - Fee Related
- 2008-10-17 MX MX2010004706A patent/MX2010004706A/es active IP Right Grant
- 2008-10-17 US US12/739,658 patent/US8569470B2/en not_active Expired - Fee Related
- 2008-10-17 KR KR1020107011928A patent/KR20100093548A/ko not_active Application Discontinuation
- 2008-10-17 CA CA2702697A patent/CA2702697A1/en not_active Abandoned
- 2008-10-17 WO PCT/CU2008/000009 patent/WO2009056076A1/es active Application Filing
- 2008-10-17 BR BRPI0817898 patent/BRPI0817898A2/pt not_active IP Right Cessation
- 2008-10-17 EP EP08845509A patent/EP2216045A1/en not_active Withdrawn
- 2008-10-17 RU RU2010121646/10A patent/RU2499046C2/ru not_active IP Right Cessation
- 2008-10-28 AR ARP080104709A patent/AR069086A1/es unknown
-
2013
- 2013-08-14 US US13/966,948 patent/US20140011216A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090143A2 (en) | 2000-05-25 | 2001-11-29 | Institut Pasteur | Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions |
US20060008474A1 (en) | 2000-05-25 | 2006-01-12 | Institut Pasteur | Polypeptides containing polymorphisms of the repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, their use in diagnostics, and in immunogenic compositions |
WO2002000695A2 (en) | 2000-06-30 | 2002-01-03 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
Non-Patent Citations (42)
Title |
---|
AGUAS, R. ET AL., LANCET INFECT DIS, vol. 6, no. 2, 2006, pages 112 - 7 |
BORDET, J.O. GENGOU, ANN INST PASTEUR, vol. 20, 1906, pages 731 - 41 |
BYRNE, S ET AL., BMC INFECT DIS, vol. 6, 2006, pages 53 |
CASSIDAY, P ET AL., J INFECT DIS, vol. 182, no. 5, 2000, pages 1402 - 8 |
CHARLES, I.G. ET AL., EUR J IMMUNOL, vol. 21, no. 5, 1991, pages 1147 - 53 |
CHARLES, I.G. ET AL., PROC NATL ACAD SCI USA, vol. 86, no. 10, 1989, pages 3554 - 8 |
CHERRY, J.D. ET AL., VACCINE, vol. 16, no. 20, 1998, pages 1901 - 6 |
CHERRY, J.D., PEDIATRICS, vol. 115, no. 5, 2005, pages 1422 - 7 |
CROWCROFT, N.S. ET AL., LANCET INFECT DIS, vol. 3, no. 7, 2003, pages 413 - 8 |
DENOEL, P. ET AL., VACCINE, vol. 23, no. 46-47, 2005, pages 5333 - 41 |
EMSLEY, P. ET AL., NATURE, vol. 381, no. 6577, 1996, pages 90 - 2 |
EVEREST, P. ET AL., MICROBIOLOGY, vol. 142, 1996, pages 3261 - 8 |
GUISO, N. ET AL., VACCINE, vol. 17, no. 19, 1999, pages 2366 - 76 |
HALLANDER, H.O. ET AL., J CLIN MICROBIOL, vol. 43, no. 6, 2005, pages 2856 - 65 |
HELLWIG, S.M. ET AL., J INFECT DIS, vol. 188, no. 5, 2003, pages 738 - 42 |
HENDERSON, I.R., INFECT IMMUN, vol. 69, no. 3, 2001, pages 1231 - 43 |
HENDERSON, I.R., TRENDS MICROBIOL, vol. 8, no. 12, 2000, pages 534 - 5 |
HERRERA AMRODRIGUEZ EG ET AL., BBRC, vol. 279, 2000, pages 548 - 551 |
HIJNEN ET AL: "The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 31, 13 July 2007 (2007-07-13), pages 5902 - 5914, XP022153002, ISSN: 0264-410X * |
HIJNEN, M. ET AL., INFECT IMMUN, vol. 72, no. 7, 2004, pages 3716 - 23 |
HIJNEN, M. ET AL., PROTEIN EXPR PURIF, vol. 41, no. 1, 2005, pages 106 - 12 |
HIJNEN, M.F. R. MOOI ET AL., INFECT IMMUN, vol. 72, no. 7, 2004, pages 3716 - 23 |
HIJNEN, M.P. G. VAN GAGELDONK ET AL., PROTEIN EXPR PURIF, vol. 41, no. 1, 2005, pages 106 - 12 |
HIJNEN, M.R. DE VOER ET AL., VACCINE, vol. 25, no. 31, 2007, pages 5902 - 14 |
IMAI, Y. ET AL., NUCLEIC ACIDS RES, vol. 19, no. 10, 1991, pages 2785 |
KING, A.J. ET AL., MICROBIOLOGY, vol. 147, 2001, pages 2885 - 95 |
LEININGER, E. ET AL., INFECT IMMUN, vol. 60, no. 6, 1992, pages 2380 - 5 |
LI, L.J. ET AL., MOL MICROBIOL, vol. 5, no. 2, 1991, pages 409 - 17 |
LIU, M. ET AL., SCIENCE, vol. 295, no. 5562, 2002, pages 2091 - 4 |
MASTRANTONIO, P. ET AL., MICROBIOLOGY, vol. 145, 1999, pages 2069 - 75 |
MATTOO, S. ET AL., FRONT BIOSCI, vol. 6, 2001, pages E168 - 86 |
MOOI, F.R ET AL., EMERG INFECT DIS, vol. 7, no. 3, 2001, pages 526 - 8 |
MOOI, F.R. ET AL., INFECT IMMUN, vol. 66, no. 2, 1998, pages 670 - 5 |
RAGUCKAS, S.E. ET AL., PHARMACOTHERAPY, vol. 27, no. 1, 2007, pages 41 - 52 |
ROBERTS, M. ET AL., VACCINE, vol. 10, no. 1, 1992, pages 43 - 8 |
RODRIGUEZ, M.E. ET AL., FEMS IMMUNOL MED MICROBIOL, vol. 46, no. 1, 2006, pages 39 - 47 |
See also references of EP2216045A1 |
SINGH, M.K. LINGAPPAN, CHEST, vol. 130, no. 5, 2006, pages 1547 - 53 |
STIBITZ, S. ET AL., NATURE, vol. 338, no. 6212, 1989, pages 266 - 9 |
STORSAETER, J. ET AL., VACCINE, vol. 21, no. 25-26, 2003, pages 3542 - 9 |
VAN AMERSFOORTH, S.C. ET AL., J CLIN MICROBIOL, vol. 43, no. 6, 2005, pages 2837 - 43 |
WEBER, C. ET AL., J CLIN MICROBIOL, vol. 39, no. 12, 2001, pages 4396 - 403 |
Also Published As
Publication number | Publication date |
---|---|
US8569470B2 (en) | 2013-10-29 |
RU2499046C2 (ru) | 2013-11-20 |
BRPI0817898A2 (pt) | 2015-05-05 |
CA2702697A1 (en) | 2009-05-07 |
MX2010004706A (es) | 2010-05-27 |
CN101878038A (zh) | 2010-11-03 |
AR069086A1 (es) | 2009-12-30 |
RU2010121646A (ru) | 2011-12-10 |
KR20100093548A (ko) | 2010-08-25 |
CN101878038B (zh) | 2013-11-06 |
EP2216045A1 (en) | 2010-08-11 |
US20140011216A1 (en) | 2014-01-09 |
US20110070265A1 (en) | 2011-03-24 |
CU23679A1 (es) | 2011-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dorji et al. | Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance | |
ES2714383T3 (es) | Vacuna TB contra la tuberculosis para impedir la reactivación | |
US20100183674A1 (en) | Compositions comprising yersinia pestis antigens | |
ES2367128T3 (es) | Procedimiento para preparar una variante del antígeno protector de superficie de erysipelothrix rhusiopathiae en e. coli. | |
Dennehy et al. | Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections | |
US20240156936A1 (en) | Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof | |
Villarino Romero et al. | Filamentous hemagglutinin of Bordetella pertussis: a key adhesin with immunomodulatory properties? | |
Sanapala et al. | Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague | |
JP6401148B2 (ja) | 抗原および抗原の組み合わせ | |
WO2009056076A1 (es) | Variantes ingenierizadas de pertactina para uso vacunal | |
WO2007112702A2 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
Liu et al. | Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker | |
RU2335505C2 (ru) | Белок nmb0928 и его применение в фармацевтических композициях | |
CN112449603A (zh) | 链球菌中毒性休克综合征 | |
WO2009000217A1 (es) | Composición farmacéutica que comprende la proteína nmb1796 | |
WO2007073705A2 (es) | Composiciones farmacéuticas que contienen la proteína nma0939 | |
Kristof | Development and characterisation of a novel vaccine for Bordetella pertussis (whooping cough) | |
WO2007112703A2 (es) | Composición farmacéutica que comprende la proteína nmb0606 | |
ES2334138T3 (es) | Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas. | |
JP2023545176A (ja) | 高用量シゲラ属(Shigella)ワクチン製剤 | |
WO2009056075A1 (es) | Composición farmacéutica que comprende la proteína nmb0873 | |
Zavadilova et al. | Rodrigo Villarino Romero, Ilona Bibova, Ondrej Cerny | |
MXPA06006266A (es) | Proteina nmb1125 y su uso en formulaciones farmaceuticas | |
MXPA06006267A (es) | Proteina nmbo928 y su uso en formulaciones farmaceuticas | |
MX2008008580A (es) | Composiciones farmaceuticas que contienen la proteina nma0939 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880114119.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08845509 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2702697 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2527/CHENP/2010 Country of ref document: IN Ref document number: MX/A/2010/004706 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008845509 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107011928 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010121646 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12739658 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0817898 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100430 |